Insomnia and nighttime restlessness in elderly patients.
Active ingredient: Phenibut
Each tablet contains 250 mg of phenibut.
Excipients: lactose monohydrate, potato starch, calcium stearate.
Due to the irritant effect of phenibut, the medicinal product should be used with caution in patients with gastrointestinal disorders. To protect the mucous membrane from the irritant effect of phenibut, lower doses should be prescribed in these patients, and the medicinal product should be taken after meals.
In case of prolonged treatment, the cellular composition of the blood and liver function test parameters should be monitored.
The medicinal product contains lactose. Therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency, or glucose-galactose malabsorption syndrome should not use this medicinal product.
Phenibut-Astrapharm is administered orally, before meals. The tablet should be swallowed whole with a sufficient amount of water. To reduce the irritant effect of phenibut on the gastrointestinal tract (see section “Special Precautions for Use”), it may be taken after meals.
Asthenic and anxiety-neurotic conditions:
Adults should receive 250–500 mg (1–2 tablets) three times daily.
The maximum single dose is:
The course of treatment is 2–3 weeks. If necessary, treatment may be extended to 4–6 weeks.
Children aged 8 to 14 years: 250 mg (1 tablet) three times daily.
Phenibut-Astrapharm 250 mg tablets may be used as an alternative dosage form.
The course of treatment is 2–6 weeks.
During exacerbations of Meniere’s disease and vestibular dysfunction of infectious origin, Phenibut-Astrapharm should be administered at a dose of 750 mg (3 tablets) three times daily for 5–7 days.
As vestibular symptoms decrease, the dose should be reduced to 250–500 mg (1–2 tablets) three times daily for 5–7 days, followed by 250 mg once daily for 5 days.
In relatively mild cases, Phenibut-Astrapharm should be administered at a dose of 250 mg (1 tablet) twice daily for 5–7 days, followed by 250 mg once daily for 7–10 days.
For dizziness associated with vestibular dysfunction of vascular or traumatic origin, Phenibut-Astrapharm should be administered at a dose of 250 mg three times daily for 12 days.
For the prevention of kinetosis, the medicinal product is administered as a single dose of 250–500 mg one hour before the expected onset of motion sickness or at the first appearance of symptoms caused by motion.
For the management of alcohol withdrawal syndrome, during the first days of treatment Phenibut-Astrapharm is administered at a dose of 250–500 mg three times daily and 750 mg at bedtime, with a gradual reduction of the daily dose to the usual adult dose.
In patients with hepatic impairment, high doses of the medicinal product may cause hepatotoxicity. Lower doses should be prescribed for patients in this group.
There are no data indicating adverse effects of Phenibut-Astrapharm in patients with impaired renal function when therapeutic doses are used.
No development of drug dependence or withdrawal syndrome was observed during the use of this medicinal product.
Isolated cases of tolerance to phenibut have been reported in the literature.
Store in the original packaging at a temperature not exceeding 25°C.
Keep out of reach of children.
